Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Theragene + Chemotherapy in Locally Advanced Pancreatic Cancer
NCT02894944Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Aug 2016
- Primary completion
- Nov 2018
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ad5-ycd/muttksr39rep-adp in pancreatic cancer (PC), sponsored by Seoul National University Hospital. Primary endpoint: Number of participants with treatment-related adverse events assessed by CTCAE v4.03 at 8 weeks. Started Aug 2016; status: completed.
02
Drugs
ad5-ycd/muttksr39rep-adp
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02894944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02894944.